Clinical efficacy of transforaminal lumbar interbody fusion (TLIF) with different interbody bone graft volume for lumbar spinal stenosis: a randomised controlled trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069064

Enrollment

Unknown

Registered

2023-03-06

Start date

2023-03-31

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar spinal stenosis

Interventions

Low intervertebral bone grafting groups:Different amount of interbody bone graft

Middle intervertebral bone grafting groups:Different amount of interbody bone graft

High intervertebral bone grafting groups:Different amount of interbody bone graft

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion: 1.40-75 years old; 2. Nerve root pain, with positive signs of nerve root compression or nerve dysfunction, confirmed by imaging that lumbar spinal canal stenosis is consistent with clinical symptoms, with symptoms lasting more than 6 weeks; 3. Transforaminal lumbar interbody fusion is required in our hospital.

Exclusion criteria

Exclusion criteria: Exclusions: 1. Previous spinal surgery; 2. Multi-level spinal fusion (>2 segments); 3. Osteoporosis (T<- 2.5 SD); 4. Serious deformity, infection, tumor and other diseases of spine; 5. Patients who are unable to tolerate anesthesia or have high risk of anesthesia evaluation and are complicated with serious medical diseases or mental disorders

Design outcomes

Primary

Measure	Time frame
Vertebral fusion rate;	—

Secondary

Measure	Time frame
Function score;	—

Countries

China

Contacts

Public ContactGuangzhi Ning

Tianjin Medical University General

yhj4830@sina.com+86 18231591549

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026